Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
about
His-tag ELISA for the detection of humoral tumor-specific immunity.Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cellsNatural history of tumor growth and immune modulation in common spontaneous murine mammary tumor modelsTherapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptDesigning vaccines to prevent breast cancer recurrence or invasive disease.Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancerIGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiologyDendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancerThe Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvantDeregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerA multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.Dendritic cells, inflammation, and breast cancer.Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Th1 epitope selection for clinically effective cancer vaccines.T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.Immunomodulation of breast cancer via tumor antigen specific Th1.Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies.
P2860
Q33338655-1BDFF8D6-6D92-4E37-9B27-A52C1EF62A6FQ33679779-6C87C47F-F900-4F72-9B32-F6CAB9DB1B13Q34149109-DCDBD091-917F-44A1-B774-C0A9293718D1Q34789746-7B02C3EA-8CFD-4708-83E3-4323A8C03401Q35193892-2EABDB0F-8EC7-4503-825A-39CAD4C429BBQ35546337-8060E8BA-F466-47B9-B6E4-F956F74B7B71Q35623804-0F431D0F-5126-4840-AF29-3E8DEC950183Q35690638-5CB19788-08FC-43B4-80ED-C86FCBB1A1D6Q36007456-18BD5034-6719-4B09-B8A5-8BE002AF43EEQ36642867-8616DEB9-5E58-42A7-B780-443372D78CBDQ36863278-2FDB890F-B718-4890-BF3C-C5B54991F7E4Q37198471-76846590-7F35-4642-9AA3-F7915FBE22FBQ37362627-E448DE70-72F8-4450-908B-585C3F5DE84BQ37369840-8C68D34C-2710-432A-9A11-40A2425B3656Q37396281-30D3F733-51E5-4697-AE88-C1415667F04EQ37456825-4F020AF7-A01E-4970-A6D6-3F675EA9BA40Q38837187-D2F9474E-B459-4822-A01D-C751CA29914BQ39038768-6FF11161-55B9-418A-BFC6-74E561E3CFE2Q42201182-86AE2745-690E-40BB-8241-773216AB4AD1Q42503675-BE900112-EDB2-4DDD-9E54-F8C13B216309Q42553514-622AD41D-A154-4C4B-BDDE-EF3EBF0E1C5EQ45730577-AEFFC45A-8A54-4308-A17C-D2D3A6905503Q47099526-78B21B80-A0F7-4339-A625-0E0D7FFAF9FCQ48191897-872720A6-347B-43D0-B748-4932CECCAF0DQ50234294-3769A575-D861-40C2-957E-BECB9515B603Q55457206-8418D943-654E-47E2-8674-99C3F55114CCQ55462258-D87129FF-C757-4AE5-B9E8-D0C6DB83D2B2
P2860
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@en
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@nl
type
label
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@en
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@nl
prefLabel
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@en
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@nl
P2093
P2860
P1433
P1476
Insulin-like growth factor-bin ...... nomodulation of breast cancer.
@en
P2093
Corazon Dela Rosa
Doreen Higgins
Jennifer Childs
Kyong Hwa Park
Mary L Disis
Patty Fintak
Thayer Wild
Vivian Goodell
Yushe Dang
P2860
P304
P356
10.1158/0008-5472.CAN-07-5891
P407
P577
2008-10-01T00:00:00Z